Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Adoption of Approved CAR-T Therapies Among US Community Hematologists/ Oncologists

Ajeet Gajra, MD MBBS, Skyler Hime, Yolaine Jeune-Smith, PhD, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-141990

Published: 2020

Journal Articles

Real-World Adverse Events Associated with Tisagenlecleucel in Acute Lymphoblastic Leukemia and Large B-Cell Lymphoma

Marjorie E Zettler, PhD MPH, Bruce Feinberg, DO, Alexandrina Balanean, Ajeet Gajra, MD MBBS

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142061

Published: 2020

Journal Articles

Assessment of Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Among U.S. Community Hematologists/ Oncologists (cH/O)

Ajeet Gajra, MD MBBS, Yamini S Rathish, Yolaine Jeune-Smith, PhD, Andrew J Klink, PhD MPH, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-142005

Published: 2020

Journal Articles

Age-Based Disparities in Clinical Trials Supporting FDA Approval of Therapies for Hematologic Malignancies

Ajeet Gajra, MD MBBS, Marjorie E Zettler, PhD MPH, Eli G Phillips, Jr., PharmD, JD, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142064

Published: 2020

Journal Articles

Real-World Effectiveness of First-Line (1L) Dasatinib Versus 1L Imatinib in Newly Diagnosed Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Andrew J Klink, PhD MPH, Scott Justin Keating, MS, John Brokars, MS, Arianna Kee, Ronda Copher, PhD, Brian Stwalley, PharmD BCGP, Bruce Feinberg, DO, Elias Jabbour, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-141125

Published: 2020

Journal Articles

Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis

Ajeet Gajra, MD MBBS, Marjorie E Zettler, PhD MPH, Andrew J Klink, PhD MPH, Bruce Feinberg, DO

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-142069

Published: 2020

Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 4057.

https://doi.org/10.1182/blood-2019-129632

Published: 2019

Journal Articles

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World

Marjorie E Zettler, PhD MPH, Chadi Nabhan, MDMBA, FACP, Ajeet Gajra, MD FACP, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 3490.

https://doi.org/10.1182/blood-2019-129553

Published: 2019

Journal Articles

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Ajeet Gajra, MD FACP, Marjorie E Zettler, PhD MPH, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Sonam Mehta, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 1952.

https://doi.org/10.1182/blood-2019-129593

Published: 2019

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Acute Myeloid Leukemia (AML)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5135.

https://doi.org/10.1182/blood-2019-130671

Published: 2019

Journal Articles

Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment

Ajeet Gajra, MD FACP, Richard Sweat, PhD, Yolaine Jeune-Smith, PhD, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5822.

https://doi.org/10.1182/blood-2019-129502

Published: 2019

Journal Articles

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Dhruv Chopra, MS, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 5378.

https://doi.org/10.1182/blood-2019-131028

Published: 2019

Journal Articles

Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, MD, Andrew J Klink, PhD MPH, Bruce Feinberg, DO, Michael McGuire, PharmD

Blood (2017) 130 (Supplement 1): 2188.

https://doi.org/10.1182/blood.V130.Suppl_1.2188.2188

Published: 2017

Journal Articles

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Jessica Chung, PhD MPH, Damion Nero, PhD, Bruce Feinberg, DO, Jonathan Kish, PhD MPH, Chadi Nabhan, MD MBA, FACP

Blood (2017) 130 (Supplement 1): 3449.

https://doi.org/10.1182/blood.V130.Suppl_1.3449.3449

Published: 2017

Journal Articles

Predictors of Emergency Room (ER) Visits and Hospitalizations in Patients with Mantle Cell Lymphoma (MCL) Treated with Chemotherapy

Bruce Feinberg, DO, Brad Schenkel, MSc, Ali McBride, PharmD,MS, Lorie Ellis, PhD, Menaka Bhor, Janna Radtchenko, Lincy S Lal

Blood (2015) 126 (23): 4526.

https://doi.org/10.1182/blood.V126.23.4526.4526

Published: 2015

Journal Articles

Predictors of Increase in Emergency Room (ER) Visits and Hospitalizations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Chemotherapy

Bruce Feinberg, DO, Brad Schenkel, MSc, Ali McBride, PharmD,MS, Lorie Ellis, PhD, Menaka Bhor, Janna Radtchenko, Lincy S Lal

Blood (2015) 126 (23): 4509.

https://doi.org/10.1182/blood.V126.23.4509.4509

Published: 2015

Journal Articles

Likelihood of a Subsequent Chemotherapy Induced Nausea and Vomiting Event In Patients with Hematologic Malignancies Receiving Chemotherapy.

Bruce Feinberg, DO, Lee S. Schwartzberg, MD, FACP, James Gilmore, PharmD, Sally Haislip, RPh, James Jackson, PharmD, MPH, Gagan Jain, PhD, Sanjeev Balu, PhD, MBA, Deborah Buchner, PhD

Blood (2010) 116 (21): 3819.

https://doi.org/10.1182/blood.V116.21.3819.3819

Published: 2010

Journal Articles

Budget Impact Model for Hypomethylating Agent Use for the Treatment of Myelodysplastic Syndromes (MDS)

Bruce Feinberg, DO, Jeffrey Scott, MD, Susan Weidner, Barry Fortner, PhD

Blood (2008) 112 (11): 2397.

https://doi.org/10.1182/blood.V112.11.2397.2397

Published: 2008

Journal Articles

Erythropoiesis-Stimulating Agents for Chemotherapy Induced Anemia: Analysis of an Electronic Medical Record Database within a Large Oncology/Hematology Practice.

Bruce Feinberg, DO, James Gilmore, PharmD, Carlos Franco, MD, Tom Gondesen

Blood (2007) 110 (11): 963.

https://doi.org/10.1182/blood.V110.11.963.963

Published: 2007

Journal Articles

Assessment of Epoetin Alfa in Patients with Myelodysplastic Syndrome Utilizing an Electronic Medical Record Database.

Bruce Feinberg, DO, James Gilmore, PharmD, Carlos Franco, MD, Tom Gondesen

Blood (2007) 110 (11): 5180.

https://doi.org/10.1182/blood.V110.11.5180.5180

Published: 2007

NARROW

Adoption of Approved CAR-T Therapies Among US Community Hematologists/ Oncologists

Real-World Adverse Events Associated with Tisagenlecleucel in Acute Lymphoblastic Leukemia and Large B-Cell Lymphoma

Assessment of Measurable Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Among U.S. Community Hematologists/ Oncologists (cH/O)

Age-Based Disparities in Clinical Trials Supporting FDA Approval of Therapies for Hematologic Malignancies

Real-World Effectiveness of First-Line (1L) Dasatinib Versus 1L Imatinib in Newly Diagnosed Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) Associated with PARP Inhibitors: A Real-World Analysis

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Adverse Events in Elderly Hodgkin Lymphoma Patients Treated with Pembrolizumab or Nivolumab in the Real World

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Real-World Utilization of Midostaurin Among Patients with Acute Myeloid Leukemia (AML)

Perceptions of Community Hematologists/Oncologists on the Potential of Data Presented at ASH 2018 and ASCO 2019 to Alter the Standard of Care for Multiple Myeloma Treatment

Real-World Utilization of Midostaurin Among Patients with Systemic Mastocytosis (SM)

Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Predictors of Emergency Room (ER) Visits and Hospitalizations in Patients with Mantle Cell Lymphoma (MCL) Treated with Chemotherapy

Predictors of Increase in Emergency Room (ER) Visits and Hospitalizations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Chemotherapy

Likelihood of a Subsequent Chemotherapy Induced Nausea and Vomiting Event In Patients with Hematologic Malignancies Receiving Chemotherapy.

Budget Impact Model for Hypomethylating Agent Use for the Treatment of Myelodysplastic Syndromes (MDS)

Erythropoiesis-Stimulating Agents for Chemotherapy Induced Anemia: Analysis of an Electronic Medical Record Database within a Large Oncology/Hematology Practice.

Assessment of Epoetin Alfa in Patients with Myelodysplastic Syndrome Utilizing an Electronic Medical Record Database.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only